VistaGen Therapeutics Inc. (VTGN)
NASDAQ (CM) NASDAQ (CM) Primary 
XMEX 
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript
Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.46 per share a year ago.
Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026
Vistagen Therapeutics' intranasal pherine drugs target nose-to-brain circuits. This taps into neuropsychiatric, women's health, and oncology indications. Their lead asset is Fasedienol, which is in Phase 3 for SAD. Its PALISADE-3 data may enable a possible NDA submission during 2026. The rest of VTGN's pipeline includes Itruvone, PH80, and PH284. However, I believe VTGN's tight runway will force them to prioritize Fasedienol's R&D.
Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript
Vistagen Therapeutics, Inc. ( VTGN ) Q2 2026 Earnings Call November 13, 2025 5:00 PM EST Company Participants Mark McPartland - Senior Vice President of Investor Relations Shawn Singh - President, CEO & Director Joshua Prince - Chief Operating Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Myles Minter - William Blair & Company L.L.C., Research Division Elemer Piros - Lucid Capital Markets, LLC, Research Division Presentation Operator Good day, everyone.
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Lags Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.42 per share a year ago.
Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2026 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Joshua S. Prince - Chief Operating Officer Mark Adrian McPartland - Senior Vice President of Investor Relations Shawn K.
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.35 per share a year ago.
Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2025 Earnings Conference Call June 17, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Mark Adrian McPartland - Senior Vice President of Investor Relations Shawn K. Singh - President, CEO & Director Conference Call Participants Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Lin Tsai - Jefferies LLC, Research Division Myles Robert Minter - William Blair & Company L.L.C.
Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication
Vistagen Therapeutics, Inc.'s results from the PALISADE-3 and PALISADE-4 studies, using fasedienol for the treatment of patients with Social Anxiety Disorder, expected in 2025. Fifth proof-of-concept of pherine drug use was achieved targeting patients with cancer cachexia; Further IND enabling efforts underway to begin phase 2 studies for this program in the United States. The global cancer cachexia market size is projected to reach $3.76 billion by 2032.
Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q3 2025 Earnings Call Transcript February 13, 2025 5:00 PM ET Company Participants Mark McPartland - Senior Vice President of Investor Relations Shawn Singh - Chief Executive Officer and Director Cindy Anderson - Chief Financial Officer Josh Prince - Chief Operating Officer Conference Call Participants John Boyle - William Blair Operator Good day. Thank you for standing by.
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.22 per share a year ago.
